



Welcome to the COVID-19 Vaccine Partner Newsletter! Here you'll find the latest news and information on COVID-19 vaccine related topics.


- [Latest News](#)
- [Clinical Updates](#)
- [Training and Events](#)
- [Resources](#)



Q: CAN THE UPDATED 2023-2024 COVID-19 VACCINES BE CO-ADMINISTERED WITH OTHER VACCINES?

A: Yes. Clinical data has shown that co-administration of COVID-19, flu and/or RSV vaccines for those who are eligible is effective. Primary care providers are encouraged to help patients determine whether they should receive multiple vaccines at once or should stagger administration. Co-administration provides an opportunity to save time for both patients and providers, avoiding the need to schedule multiple appointments. Overall, it is recommended that anyone who is eligible should receive all applicable respiratory disease vaccines this fall for optimal protection.

Latest News



CDC ENDORSES 2023-2024 COVID-19 VACCINES FOR USE

Following [FDA regulatory action](#), the [Centers for Disease Control and Prevention \(CDC\)](#) [has recommended](#) updated 2023-2024 COVID-19 vaccines for everyone 6 months and older that target the omicron subvariant XBB.1.5. Bivalent mRNA COVID-19 vaccines are no longer authorized or available in the United States. The new COVID-19 vaccine recommendations are as follows:

- Children 6 months – 4 years old who are unvaccinated should complete a multidose initial series (2 doses of Moderna or 3 doses of Pfizer-BioNTech 2023-2024 COVID-19 vaccine).
- Children 6 months – 4 years old who were previously vaccinated are eligible to receive 1 or 2 doses of a 2023-2024 COVID-19 vaccine (timing and number of doses to administer depends on the previous COVID-19 vaccine[s] received).
- Anyone aged 5 years and older regardless of previous vaccination is eligible to receive 1 dose of a 2023-2024 COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine.
- People who are moderately or severely immunocompromised should complete a 3-dose initial series with at least one dose of the 2023-2024 COVID-19 vaccine and may receive 1 or more additional 2023-2024 COVID-19 vaccine doses.

While 2023-2024 COVID-19 vaccines have begun arriving in Washington state, supply may be limited for some time as the new distribution mechanisms with commercialization of COVID-19 vaccines are initiated. COVID-19 vaccines will be provided through the [Childhood Vaccine Program](#), [Adult Vaccine Program/Bridge Access Program](#), and through commercial purchase for those with insurance. Please help your patient populations and communities understand these considerations and thank them for their patience.

CDC's [Interim Clinical Considerations for Use of COVID-19 Vaccines page](#) has been updated to provide further clinical guidance on vaccine administration under the updated recommendations. The original Novavax COVID-19 vaccine is currently available for those aged 12 and older, but an updated version that targets the omicron subvariant is currently being evaluated and may be available later this year.



THE BRIDGE ACCESS PROGRAM OFFICIALLY LAUNCHES

The Centers for Disease Control and Prevention's (CDC) [Bridge Access Program](#) has officially launched, providing continued access to COVID-19 vaccines at no cost for the estimated 25-30 million adults who would have otherwise lost access now that these products have transitioned to the commercial market. All children 18 years of age and under have access to COVID-19 vaccines via the [Childhood Vaccine Program](#) at no cost to the patient. Under- and uninsured adults can now access COVID-19 vaccine via the Bridge Access Program, which includes partnership with CVS, Walgreens, other pharmacies across Washington and additional Adult Vaccine Providers. CDC's Bridge Access Program provides no-cost COVID-19 vaccines to adults without health insurance and adults whose insurance does not cover all COVID-19 vaccine costs. No-cost COVID-19 vaccines through this program will be available until December 31, 2024, while supplies last. Updates to [Vaccines.gov](#) will be made in the coming weeks to include all pharmacy locations of the Bridge Access Program.

To support equitable access to COVID-19 vaccines for adults through the Bridge Access program, CDC is:

- Launching a communications campaign with digital and other advertisements beginning in October 2023. All [communication resources](#), such as flyers and social media posts, are downloadable and adaptable should partners want to disseminate them directly through your websites, offices, and social media channels. They are available in English and Spanish.
- Calling on immunization managers and healthcare providers, as trusted sources of information, to support COVID-19 vaccinations and Bridge Access Program.
- Sharing a [communication toolkit for partners](#) to expand access to no-cost COVID-19 vaccines and promote the Bridge Access Program. The toolkit includes frequently asked questions and communication resources.

There are three more office hour sessions available for regular updates and opportunities to address your questions regarding the Bridge Program and commercialization.

Office Hours run from 12:30pm - 1:30pm PT on the following dates:

- Sep 27, 2023
- Oct 11, 2023
- Oct 25, 2023

Click the link below to join the webinar:

[https://cdc.zoomgov.com/j/1608962758?
pwd=RVBFRzJRRE9lb3R2TXo1S3F3QW9nQT09](https://cdc.zoomgov.com/j/1608962758?pwd=RVBFRzJRRE9lb3R2TXo1S3F3QW9nQT09)

Bridge Access Program FAQ



UPDATED DOH COVID-19 VACCINE WEBPAGES & RESOURCES

The Washington State Department of Health's (DOH) COVID-19 Vaccine Health Education team has been hard at work to update webpages and materials following the updated 2023-2024 COVID-19 vaccine [recommendations](#). Below is a list of resources that are now up to date and ready for your use:

General Public Webpages:

- [COVID-19 Vaccine Information | Washington State Department of Health](#)
- [Vaccinating Youth | Washington State Department of Health](#)
- [COVID-19 Vaccine Frequently Asked Questions | Washington State Department of Health](#)

Provider Webpages:

- [COVID-19 Vaccine Information for Health Care Providers | Washington State Department of Health](#)
- [About the COVID-19 Vaccines | Washington State Department of Health](#)
- [Vaccinating Youth | Washington State Department of Health](#)
- [Clinical Information for COVID-19 Vaccine Providers | Washington State Department of Health](#)
- [Toolkit and Resources | Washington State Department of Health](#)


Resources for General Public:

- [Getting Vaccinated to Protect Against COVID-19 Illness](#)
- [Pediatric COVID-19 Vaccines What Parents/Guardians Should Know \(wa.gov\)](#)

Resources for Providers:

- [Health Care Provider Discussion Guide: Building Confidence in the COVID-19 Novavax Vaccine](#)
- [DOH 820-025 Pediatric Provider Discussion Guide: Building Parental/Guardian Confidence in COVID-19 Vaccination](#)
- [2023-2024 COVID-19 Vaccine Product Characteristics and Information](#)

Stay tuned as we continue to update and create materials in the coming weeks.



COVID-19 IMMUNITY WANES OVER TIME, VACCINES REMAIN BEST DEFENSE

The Centers for Disease Control and Prevention (CDC) reports that immunity against COVID-19 is stronger today than at any other point since COVID-19 emerged. Immunity from vaccines and/or previous infection acts like a shield against the virus and reduces your chance of getting a serious infection. The CDC stresses that we still need to be cautious because immune protection decreases over time. This is especially important for older adults, who make up most of the hospitalizations and deaths from COVID-19 ([currently increasing in the United States](#)).

The virus that causes COVID-19 continues to change. For example, researchers are currently learning more about a [newer variant called BA.2.86](#). It's a reminder to use the tools we have to fight COVID-19. The newest 2023-2024 COVID-19 vaccine targets the omicron subvariant XBB.1.5 and is our best defense against COVID-19 disease this year.



FALL AND WINTER 2023 IMMUNIZATION MESSAGING

Following the Center for Disease Control and Prevention's updated COVID-19 vaccine recommendations for 2023-2024, Public Health Communications Collaborative (PHCC) has created immunization messaging for the fall and winter respiratory illness season. This resource reflects the latest COVID-19 vaccine guidance and answers questions about the array of respiratory illnesses—COVID-19, the flu, and RSV—within your community, including guidance about whether to get multiple vaccines at one time.

PHCC also offers a customizable social graphic toolkit [here](#).

[View PHCC Messaging](#)

Clinical Updates



COVID-19 VACCINE PRODUCT CHARACTERISTICS TABLE UPDATED FOR 2023-2024

With the addition of updated 2023-2024 COVID-19 vaccines and deauthorization of bivalent mRNA COVID-19 vaccines, your COVID-19 vaccine inventory will start to look different. We have updated our [COVID-19 Vaccine Product Characteristics Table](#) to serve as a convenient, one page comprehensive reference guide for all COVID-19 vaccine products in your inventory, including information on which vaccine products are no longer authorized.

2023-2024 COVID-19 Vaccine Product Characteristics and Information

Vaccine Manufacturer/Brand Name	Age Group	Vial Cap/Label Color	Dose	Dose Volume	Amount of Diluent Needed per Vial	Doses per Vial
Pfizer-BioNTech/Comirnaty 2023-2024 Formula adolescent/adult single-dose vial	12 years+	Gray	30 mcg	0.3 mL	NO DILUTION	10/package
Pfizer-BioNTech 2023-2024 Formula pediatric single-dose vial	5-11 years	Blue	10 mcg	0.3 mL	NO DILUTION	10/package
Pfizer-BioNTech 2023-2024 Formula pediatric/infants multi-dose vial	6 months-4 years	Yellow	3 mcg	0.3 mL	1.1 mL	3
Moderna/Spikevax 2023-2024 Formula adolescent/adult single-dose vial	12 years +	Dark Blue	50 mcg	0.5mL	NO DILUTION	10/package
Moderna 2023-2024 Formula pediatric single-dose vial	6 months-11 years	Dark Blue Cap/ Green Label	25 mcg	0.25mL	NO DILUTION	10/package
Novavax adolescent/adult primary series	12 years +	Royal Blue	5 mcg rS and 50 mcg of Matrix-M adjuvant	0.5 mL	NO DILUTION	10
Deauthorized: Pfizer-BioNTech adolescent/adult bivalent	12 years +	Gray	30 mcg	0.3 mL	NO DILUTION	6
Deauthorized: Pfizer-BioNTech adolescent/adult bivalent single-dose vial	12 years +	Gray	30 mcg	0.3 mL	NO DILUTION	10/package
Deauthorized: Pfizer-BioNTech pediatric bivalent	5-11 years	Orange	10 mcg	0.2 mL	1.3 mL	10 (after dilution)
Deauthorized: Pfizer-BioNTech pediatric/infants bivalent	6 months-4 years	Maroon	3 mcg	0.2 mL	2.2 mL	10 (after dilution)
Deauthorized: Moderna adolescent/adult bivalent	12 years +	Dark Blue Cap/ Gray Label	50 mcg	0.5mL	NO DILUTION	5
Deauthorized: Moderna pediatric bivalent	6 months-11 years	Dark Blue Cap/ Gray Label	25 mcg	0.25 mL	NO DILUTION	10
Deauthorized: Moderna pediatric/infants bivalent	6 months-5 years	Magenta Cap/ Yellow Label	10 mcg	0.2mL	NO DILUTION	2



DOH 825-047 September 2023

To request this document in another format, call 1-800-525-0127. Text or hard of hearing customers, please call 711 (Washington Relay) or email ask@doh.wa.gov.

Please review

[CDC's interim COVID-19 immunization schedule](#) for ages 6 months and older.



DOH COVID-19 VACCINATION PROGRAM DISCONTINUED

As of September 12, the updated COVID-19 vaccines have been transitioned from being purchased by the U.S. government to being available on the commercial market like many other vaccines. COVID-19 vaccines are also available for ordering through regular Department of Health vaccine programs, [Childhood Vaccine Program \(CVP\)](#) and/or [Adult Vaccine Program \(AVP\)](#).

With the US Government no longer purchasing COVID-19 vaccines for administration through the CDC COVID-19 Vaccination Program, the Washington State COVID-19 Vaccination Program has discontinued. Providers are asked to submit a signed acknowledgement of their [disenrollment](#) from the program to COVID.Vaccine@doh.wa.gov.

Please review this [Comparison of Vaccine Program Requirements](#) to see how CVP and AVP differ from each other, and from the COVID-19 program.



ORDERING QUANTITIES AND WASTE OF COMMERCIAL COVID-19 VACCINES

Following the commercialization of COVID-19 vaccines, we are encouraging providers to order smaller quantities of COVID-19 vaccine more frequently rather than placing large, bulk orders. Childhood Vaccine Program and Adult Vaccine Program providers are able to place orders for COVID-19 vaccines as frequently as they need to in the IIS. The minimum order quantity for every vaccine is 10 doses, except for the Pfizer 6 months to 4 years which is 30 doses.

Please note on the storage and handling chart below that Pfizer vaccines are only viable for up to 10 weeks if they are stored in a refrigerator.

	UNIT TYPE	UNPUNCTURED VIALS	PUNCTURED VIALS
Moderna	Refrigerator	2°C to 8°C (36°F to 46°F) for up to 30 days	N/A
	Freezer	-50°C to -15°C (-58°F to 5°F) until the expiration date	N/A
	Other	8°C and 25°C (46°F and 77°F) for a total of 24 hours	N/A
Pfizer-BioNTech	Refrigerator	2°C to 8°C (36°F to 46°F) for up to 10 weeks	2°C to 8°C (36°F to 46°F) Up to 12 hours
	Ultra-Cold Freezer	-130°F to -76°F (-90°C to -60°C) until the expiration date	N/A
	Other	8°C and 25°C (46°F and 77°F) for a total of 12 hours.	N/A
Novavax	Refrigerator	2°C to 8°C (36°F to 46°F) until the expiration date	2°C to 8°C (36°F to 46°F) up to 6 hours

Additionally, we are encouraging ordering of smaller quantities to reduce waste of COVID-19 vaccines. Following commercialization, any waste of COVID-19 vaccines will be monitored and evaluated.



COVID-19 VACCINE ALLOCATION & EXPECTED SHIPPING DELAYS

As COVID-19 vaccines become a routine vaccine offered by the Washington State Childhood Vaccine Program and Adult Vaccine Program, the COVID-19 vaccines available to order are currently under allocation. You may notice your vaccine orders are reduced initially to accommodate for the limited number of doses currently available.

Please note you may order COVID-19 vaccine any time throughout the month. Please order small amounts more frequently initially as we transition these vaccines into our routine programs. See the COVID-19 vaccines available below. We expect some presentations to be available soon.

Brand & Age Range	NDC	Presentation	Doses/Package/Min Order Size
Moderna, ages 12 years to 18 years	80777-0102-95	SDV	10
Pfizer-BioNTech, ages 12 years to 18 years	00069-2362-10	SDV	10
Pfizer-BioNTech, ages 5 years to 11 years	59267-4331-02	SDV	10
Pfizer-BioNTech, ages 6 months to 4 years	59267-4315-02	MDV-3	30
**Moderna, ages 6 months to 11 years	80777-0287-92	SDV	10
**Novavax, ages 12 years to 18 years	80631-0105-02	MDV-5	10
**This vaccine coming soon to CVP			

Shipping Delays Expected- Our distributor, McKesson has recently experienced a larger than normal volume of orders which is causing delays in vaccine shipments. Thank you for your patience and understanding as McKesson works through the backlog of vaccine shipments.



MODERNA 6 MONTHS TO 11 YEARS VACCINE ORDERING

Ordering for Moderna 6 months to 11 years vaccine was turned on in the WAIS at 2:30PM, Thursday, September 21st. This vaccine is a single dose vial, and the minimum order quantity is 10 doses/order. Childhood Vaccine Providers are able to order COVID-19 vaccine as frequently as they need to, and we encourage providers to place smaller orders more frequently rather than placing large bulk orders. Please reach out to covid.vaccine@doh.wa.gov with any questions.

WASHINGTON STATE — —
IMMUNIZATION
— — INFORMATION SYSTEM

REMINDERS FOR PROVIDERS

The COVID-19 vaccine is available to order through the Childhood Vaccine Program, and you may notice some differences from the pandemic COVID-19 Vaccine Program:

1. Only order what you can use and consider your storage capacity, order quantities can be small with a minimum order size of ten.
2. Orders can be placed anytime throughout the month, similar to flu vaccine orders for children.
3. All CVP accountability requirements apply to COVID-19 vaccines so ensure your temperature logs and inventory reports are up to date prior to placing your COVID-19 vaccine order.
4. Depots of COVID-19 vaccine are no longer allowed. Every provider should place their own COVID-19 vaccine order for shipment directly to their clinic for only the number of doses your clinic can use.
5. Keep waste to a minimum, order appropriately and submit your vaccine returns when appropriate. Do not discard vaccine.
6. Ancillary kits will no longer be provided. Please ensure you have adequate supply of syringes, needles, and other ancillary supplies to administer COVID-19 vaccines.
7. COVID-19 vaccines will no longer ship within 48 hours but will now align with routine vaccine shipping timeframes.



COVID-19 VACCINE CODES

Any COVID-19 vaccine obtained after commercialization shall use the code/funding structure below:

- Bridge Vaccine – Dose Eligibility V23 and Funding Source VXC50
- Pharmacy Program – Dose Eligibility V01 and Funding Source VXC50 or VXC52
- Patient eligibility and funding codes shall align with the [state eligibility guide](#) for all other COVID-19 vaccines.
- Public Supplied VFC vaccine (state supplied VFC vaccine) – Dose Eligibility V02, V03, V04, and V05; Funding Source VXC51.
- Public Supplied Non-VFC vaccine (state supplied vaccines provided to CHIP and/or privately insured children) – Dose Eligibility V22 or V25; Funding Source VXC52.
- Public Supplied AVP vaccine – Dose Eligibility V23; Funding Source VXC52.
- Private Purchase vaccine (vaccine purchased outside of these programs) – Dose Eligibility V01 and V24; Funding Source PHC70.

We recommend vaccine clinic staff reach out to their EHR and IT support teams to be sure any system updates needed to support these changes are identified.

Training and Events



POWER OF PROVIDERS FALL WEBINARS

Power of Providers (POP) is offering four peer-to-peer webinars this fall to address vaccine fatigue and behavioral health topics for health care workers. POP is pursuing continuing education (CE) accreditation credits for physicians, medical assistants and nurses for the webinars listed below and will provide additional information on how to apply for CE credit soon.

All webinars below are held from 12:00PM-1:00PM PT.

- October 18: COVID-19 Disaster Cascade Recovery Updates
- November 3: Vaccine Fatigue: Addressing the Elephant in the Room
- November 17: Beyond Burnout & Resilience: Purpose and Adaptability for Health Care Providers
- December 8: Beyond Burnout & Resilience: Connection and Hope for Health Care Providers

[Register & View Past Webinars](#)



COCA CALL: RECOMMENDATIONS FOR INFLUENZA, COVID-19 AND RSV VACCINES FOR OLDER ADULTS

Earlier this week CDC presenters provided updates about the latest clinical considerations for administering influenza (flu), COVID-19 and respiratory syncytial virus (RSV) vaccines to adults 60 years and older and discussed resources and communication strategies that may help facilitate vaccination. You can visit [this webpage](#) for more information and to view the hour-long webinar recording.



SAFEGUARDING LONG-TERM CARE RESIDENTS FROM COVID-19, FLU, AND RSV

Tuesday, October 17 from 10:00AM-11:00AM PT

Join us October 17 at 10:00 a.m. for an informative webinar on best practices for safeguarding long-term care residents from COVID-19, influenza, and RSV. Learn crucial strategies to ensure their health and well-being in the face of respiratory illnesses.

[Register Here](#)

Resources

FOR EVERYONE

- [Myths and Facts About COVID-19 Vaccines | CDC](#)
- [FAQs About COVID-19 Vaccines | CDC](#)
- [COVID-19 Vaccines for Children and Teens | CDC](#)
- The CDC's [After Getting the Vaccine](#) page shares what you can expect after getting vaccinated, including common side effects.
- [What To Do If You Were Potentially Exposed to Someone With COVID-19 \(PDF\)](#).
- [Symptom Decision Tree for Non-Health Care Settings and the Public \(PDF\)](#).

FOR INDUSTRY

- [Guidance for Businesses and Organizations \(Non-Health Care\)](#).

FOR SCHOOLS AND CHILD CARE FACILITIES

- [K-12 Schools 2022-2023 Requirements \(PDF\)](#).
- [COVID-19 Vaccines: Pediatric Vaccine Toolkit for Schools](#) This toolkit provides a variety of resources for schools, including parent handouts, backpack stuffers, and sample communications.

FOR LONG-TERM CARE FACILITIES

- [SARS-CoV-2 Infection Prevention and Control in Health Care Settings Toolkit](#).
- [What to Do If You Identify a COVID-19 Case in Your Hospital](#).
- [LTCF Visitor Announcement Sign](#) – Visitation rules signage.


FOR HEALTH PARTNERS

- [COVID-19 Vaccines: Pediatric Vaccine Toolkit for Providers](#) - This toolkit provides a variety of resources for providers, such as parent handouts and sample communications.
- [Pediatric Healthcare Professionals COVID-19 Vaccination Toolkit | CDC](#)
- [Pfizer-BioNTech COVID-19 Vaccine Questions | CDC](#)
- [How to Talk to Your Patients About COVID-19 Vaccination | CDC](#)
- [Clinical Resources for Pfizer-BioNTech COVID-19 Vaccine](#)
- [Clinical Resources for Moderna COVID-19 Vaccine](#)



SIGN UP FOR THIS NEWSLETTER!

If you aren't already signed up for the COVID-19 Vaccine Partner Newsletter, please visit the Department of Health's email subscribers page [here](#). Once you enter your email, on the next page expand the Immunization topic, select the COVID-19 Vaccine Partner Newsletter, and click submit.



This newsletter summarizes content beginning the week of September 10, 2023 and was sent out on September 22, 2023.

